Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA Combined with KPD Regimen for Refractory/Relapsed Multiple Myeloma
NCT06158412Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin in multiple myeloma (MM), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Overall Response Rate up to 26 months. Started Nov 2023; status: recruiting.
02
Drugs
tretinoin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06158412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158412.